JP2006520386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006520386A5 JP2006520386A5 JP2006507111A JP2006507111A JP2006520386A5 JP 2006520386 A5 JP2006520386 A5 JP 2006520386A5 JP 2006507111 A JP2006507111 A JP 2006507111A JP 2006507111 A JP2006507111 A JP 2006507111A JP 2006520386 A5 JP2006520386 A5 JP 2006520386A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- heteroatoms
- disorder
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000005842 heteroatom Chemical group 0.000 claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 22
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 239000001301 oxygen Substances 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 239000011593 sulfur Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 102000004000 Aurora Kinase A Human genes 0.000 claims 3
- 108090000461 Aurora Kinase A Proteins 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 3
- 102000001267 GSK3 Human genes 0.000 claims 3
- 108060006662 GSK3 Proteins 0.000 claims 3
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 3
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 3
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000016738 bone Paget disease Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 238000002636 symptomatic treatment Methods 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 229920002527 Glycogen Polymers 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010039 central nervous system leukemia Diseases 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 230000019100 sperm motility Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000001720 vestibular Effects 0.000 claims 1
- 0 **C(C(*)*)NC(c1c(*)c(C(*2)=C(*)*N=C2[U]*)c(*)[n]1*)=O Chemical compound **C(C(*)*)NC(c1c(*)c(C(*2)=C(*)*N=C2[U]*)c(*)[n]1*)=O 0.000 description 10
- YCHIQDLEZPUYSN-UHFFFAOYSA-N CCC(CO)Nc1nc(-c2c(C)[nH]c(C(O)=O)c2C)ccn1 Chemical compound CCC(CO)Nc1nc(-c2c(C)[nH]c(C(O)=O)c2C)ccn1 YCHIQDLEZPUYSN-UHFFFAOYSA-N 0.000 description 2
- QCPZQPYYXQYANV-UHFFFAOYSA-N CCOC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O QCPZQPYYXQYANV-UHFFFAOYSA-N 0.000 description 2
- ZOAZDMWVSSHHFN-UHFFFAOYSA-N CC(C)(C)OC(c1c(C)c(-c2ccnc(N)n2)c(C)[nH]1)=O Chemical compound CC(C)(C)OC(c1c(C)c(-c2ccnc(N)n2)c(C)[nH]1)=O ZOAZDMWVSSHHFN-UHFFFAOYSA-N 0.000 description 1
- KADPBNIJENGIJE-UHFFFAOYSA-N CC(C)(C)OC(c1c(C)c(-c2ccnc(Nc(cn3)ccc3Cl)n2)c(C)[nH]1)=O Chemical compound CC(C)(C)OC(c1c(C)c(-c2ccnc(Nc(cn3)ccc3Cl)n2)c(C)[nH]1)=O KADPBNIJENGIJE-UHFFFAOYSA-N 0.000 description 1
- PUNPHGBHJGIAKI-UHFFFAOYSA-N CC(C)(C)OC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O Chemical compound CC(C)(C)OC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O PUNPHGBHJGIAKI-UHFFFAOYSA-N 0.000 description 1
- UCMOSKVKJINLGG-UHFFFAOYSA-N CC(C)(C)OC(c1c(C)c(C2N=C(Nc(cc3)ccc3S(N)(=O)=O)N=CC2)c(C)[nH]1)=O Chemical compound CC(C)(C)OC(c1c(C)c(C2N=C(Nc(cc3)ccc3S(N)(=O)=O)N=CC2)c(C)[nH]1)=O UCMOSKVKJINLGG-UHFFFAOYSA-N 0.000 description 1
- LMUUJXSADZXOLJ-FIHRGKNVSA-N CC(C)=C(/C(/C)=C(\C=N)/S(NCc1cc(Cl)ccc1)(=O)=O)/C(/N=C(N)N)=C/C=C Chemical compound CC(C)=C(/C(/C)=C(\C=N)/S(NCc1cc(Cl)ccc1)(=O)=O)/C(/N=C(N)N)=C/C=C LMUUJXSADZXOLJ-FIHRGKNVSA-N 0.000 description 1
- PLCZOBMIYARGKJ-SDXDJHTJSA-N CC(C)=C(/C(/CO)=C(/C(NCc1cc(Cl)ccc1)=O)\N)c1ccnc(NC)n1 Chemical compound CC(C)=C(/C(/CO)=C(/C(NCc1cc(Cl)ccc1)=O)\N)c1ccnc(NC)n1 PLCZOBMIYARGKJ-SDXDJHTJSA-N 0.000 description 1
- KJGNHIDGJSFMRT-UHFFFAOYSA-N CC(C)Nc1nc(-c2c(C)[nH]c(C(O)=O)c2C)ccn1 Chemical compound CC(C)Nc1nc(-c2c(C)[nH]c(C(O)=O)c2C)ccn1 KJGNHIDGJSFMRT-UHFFFAOYSA-N 0.000 description 1
- RXTVXKQXFADFRW-UHFFFAOYSA-N CC(C)Nc1nc(-c2c(C)[nH]c(C(O)O)c2C)ccn1 Chemical compound CC(C)Nc1nc(-c2c(C)[nH]c(C(O)O)c2C)ccn1 RXTVXKQXFADFRW-UHFFFAOYSA-N 0.000 description 1
- RQAONTQWJJSRNO-UHFFFAOYSA-N CC(c1c(C)c(-c2ccnc(Nc3cccc(OCc4ccccc4)c3)n2)c(C)[nH]1)=O Chemical compound CC(c1c(C)c(-c2ccnc(Nc3cccc(OCc4ccccc4)c3)n2)c(C)[nH]1)=O RQAONTQWJJSRNO-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- DBPNIYLDFQKLHY-UHFFFAOYSA-N CCCNC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O Chemical compound CCCNC(c1c(C)c(-c2ccnc(Nc3ccccc3)n2)c(C)[nH]1)=O DBPNIYLDFQKLHY-UHFFFAOYSA-N 0.000 description 1
- QXCWKNHFMUGDJK-UHFFFAOYSA-N CCNc1nc(-c2c(C)[nH]c(C(OC(C)(C)C)=O)c2C)ccn1 Chemical compound CCNc1nc(-c2c(C)[nH]c(C(OC(C)(C)C)=O)c2C)ccn1 QXCWKNHFMUGDJK-UHFFFAOYSA-N 0.000 description 1
- HBFBVAWDOCITBN-VLKJOQIWSA-N CCOC(/C(/C)=C(/C(/c1ccnc(Nc2cccc(Cl)c2)n1)=C(/C)\N)\c1ccccc1)=O Chemical compound CCOC(/C(/C)=C(/C(/c1ccnc(Nc2cccc(Cl)c2)n1)=C(/C)\N)\c1ccccc1)=O HBFBVAWDOCITBN-VLKJOQIWSA-N 0.000 description 1
- TZKKMGXXCMVCRC-UHFFFAOYSA-N CCOC(C(C)(C1C)NC(C)=C1c1ccnc(NC2CCCCC2)n1)=O Chemical compound CCOC(C(C)(C1C)NC(C)=C1c1ccnc(NC2CCCCC2)n1)=O TZKKMGXXCMVCRC-UHFFFAOYSA-N 0.000 description 1
- YZDASUQYBPJAOW-UHFFFAOYSA-N CCOC(c([nH]c(C)c1-c2ccnc(Nc(cc3)cnc3Cl)n2)c1-c1ccccc1)=O Chemical compound CCOC(c([nH]c(C)c1-c2ccnc(Nc(cc3)cnc3Cl)n2)c1-c1ccccc1)=O YZDASUQYBPJAOW-UHFFFAOYSA-N 0.000 description 1
- GTYNMXWARRPXKA-UHFFFAOYSA-N CCOC(c([nH]c(C)c1-c2ccnc(Nc3cccc(OCc4ccccc4)c3)n2)c1-c1ccccc1)=O Chemical compound CCOC(c([nH]c(C)c1-c2ccnc(Nc3cccc(OCc4ccccc4)c3)n2)c1-c1ccccc1)=O GTYNMXWARRPXKA-UHFFFAOYSA-N 0.000 description 1
- BRJWXAMWKDGZMK-UHFFFAOYSA-N CCOC(c([nH]c(C)c1-c2ccnc(Nc3ccccc3)n2)c1-c1ccccc1)=O Chemical compound CCOC(c([nH]c(C)c1-c2ccnc(Nc3ccccc3)n2)c1-c1ccccc1)=O BRJWXAMWKDGZMK-UHFFFAOYSA-N 0.000 description 1
- GTGDTFVPAYNSKP-UHFFFAOYSA-N CCOC(c1c(C)c(-c2c(CO)cnc(NC3CCCCC3)n2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(-c2c(CO)cnc(NC3CCCCC3)n2)c(C)[nH]1)=O GTGDTFVPAYNSKP-UHFFFAOYSA-N 0.000 description 1
- ZGGXJRXZIAKSDN-UHFFFAOYSA-N CCOC(c1c(C)c(-c2ccnc(Nc(cc3)ccc3Cl)n2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(-c2ccnc(Nc(cc3)ccc3Cl)n2)c(C)[nH]1)=O ZGGXJRXZIAKSDN-UHFFFAOYSA-N 0.000 description 1
- WERSAWQPABAEDQ-UHFFFAOYSA-N CCOC(c1c(C)c(-c2ccnc(Nc(cc3)ccc3F)n2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(-c2ccnc(Nc(cc3)ccc3F)n2)c(C)[nH]1)=O WERSAWQPABAEDQ-UHFFFAOYSA-N 0.000 description 1
- ILLYXVCQSSPMBX-UHFFFAOYSA-N CCOC(c1c(C)c(-c2ccnc(Nc3cc(O)ccc3)n2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(-c2ccnc(Nc3cc(O)ccc3)n2)c(C)[nH]1)=O ILLYXVCQSSPMBX-UHFFFAOYSA-N 0.000 description 1
- XIQCTMGZMSSOEG-UHFFFAOYSA-N CCOC(c1c(C)c(C2(C)NC(NC(C)=C)N=CC2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(C2(C)NC(NC(C)=C)N=CC2)c(C)[nH]1)=O XIQCTMGZMSSOEG-UHFFFAOYSA-N 0.000 description 1
- GUSMARCYEQWNMV-UHFFFAOYSA-N CCOC(c1c(C)c(C2=CC(C)NC(Nc(cc3)ccc3Cl)=N2)c(C)[nH]1)=O Chemical compound CCOC(c1c(C)c(C2=CC(C)NC(Nc(cc3)ccc3Cl)=N2)c(C)[nH]1)=O GUSMARCYEQWNMV-UHFFFAOYSA-N 0.000 description 1
- ZAYFZAVCFFQWDF-LBPRGKRZSA-N CC[C@@H](CO)Nc1nc(-c2c(C)[nH]c(C(OCC)=O)c2C)ccn1 Chemical compound CC[C@@H](CO)Nc1nc(-c2c(C)[nH]c(C(OCC)=O)c2C)ccn1 ZAYFZAVCFFQWDF-LBPRGKRZSA-N 0.000 description 1
- FMFDRORWWFWKED-UHFFFAOYSA-N Cc([nH]c(C(NCc(cc1)ccc1F)=O)c1CC(F)(F)F)c1-c(nc(N)nc1)c1O Chemical compound Cc([nH]c(C(NCc(cc1)ccc1F)=O)c1CC(F)(F)F)c1-c(nc(N)nc1)c1O FMFDRORWWFWKED-UHFFFAOYSA-N 0.000 description 1
- CIBQDQKVLHRGOE-UHFFFAOYSA-N Cc([nH]c(C(NCc(cc1)ccc1F)=O)c1CN(C)C)c1-c(nc(N)nc1)c1F Chemical compound Cc([nH]c(C(NCc(cc1)ccc1F)=O)c1CN(C)C)c1-c(nc(N)nc1)c1F CIBQDQKVLHRGOE-UHFFFAOYSA-N 0.000 description 1
- NMJMQJFKZWYGAQ-QPSGOUHRSA-N Cc1c(C(/N=C/c(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(N)nc1)c1O Chemical compound Cc1c(C(/N=C/c(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(N)nc1)c1O NMJMQJFKZWYGAQ-QPSGOUHRSA-N 0.000 description 1
- LGEXVDKKBLLTMB-IZBUIJGWSA-N Cc1c(C(CC(CC2)CCC2O)=O)[nH]c(C)c1/C(/N)=C/C=N\C(Nc1ccccc1)=C Chemical compound Cc1c(C(CC(CC2)CCC2O)=O)[nH]c(C)c1/C(/N)=C/C=N\C(Nc1ccccc1)=C LGEXVDKKBLLTMB-IZBUIJGWSA-N 0.000 description 1
- CWEURPXSCBEGRL-UHFFFAOYSA-N Cc1c(C(N)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 Chemical compound Cc1c(C(N)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 CWEURPXSCBEGRL-UHFFFAOYSA-N 0.000 description 1
- GMAAYPYUMWGEDN-VOTSOKGWSA-N Cc1c(C(NC(/C=C/O)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c(nc(NCC(F)(F)F)nc1)c1F Chemical compound Cc1c(C(NC(/C=C/O)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c(nc(NCC(F)(F)F)nc1)c1F GMAAYPYUMWGEDN-VOTSOKGWSA-N 0.000 description 1
- PBYOIMZXRZIDCC-SOFGYWHQSA-N Cc1c(C(NC(/C=C/O)c2cc(Cl)ccc2)=O)[nH]c(CO)c1-c1ccnc(NOCC(F)(F)F)n1 Chemical compound Cc1c(C(NC(/C=C/O)c2cc(Cl)ccc2)=O)[nH]c(CO)c1-c1ccnc(NOCC(F)(F)F)n1 PBYOIMZXRZIDCC-SOFGYWHQSA-N 0.000 description 1
- ZWELQEAMLSLQHK-VQHVLOKHSA-N Cc1c(C(NC(/C=C/O)c2cccc(Cl)c2)=O)[nH]c(C)c1-c1ccnc(NCC(F)(F)F)n1 Chemical compound Cc1c(C(NC(/C=C/O)c2cccc(Cl)c2)=O)[nH]c(C)c1-c1ccnc(NCC(F)(F)F)n1 ZWELQEAMLSLQHK-VQHVLOKHSA-N 0.000 description 1
- IYRMDUGZGSYXDY-UHFFFAOYSA-N Cc1c(C(NC(C2)Cc3c2cccc3)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 Chemical compound Cc1c(C(NC(C2)Cc3c2cccc3)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 IYRMDUGZGSYXDY-UHFFFAOYSA-N 0.000 description 1
- BXYRFABRROFXNE-UHFFFAOYSA-N Cc1c(C(NC(CO)c(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(NC(CC(F)(F)F)O)nc1)c1F Chemical compound Cc1c(C(NC(CO)c(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(NC(CC(F)(F)F)O)nc1)c1F BXYRFABRROFXNE-UHFFFAOYSA-N 0.000 description 1
- DMXCLXKYCISDMZ-UHFFFAOYSA-N Cc1c(C(NC2(CO)CCCC2)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 Chemical compound Cc1c(C(NC2(CO)CCCC2)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 DMXCLXKYCISDMZ-UHFFFAOYSA-N 0.000 description 1
- JBYGMRAUWMALBQ-UHFFFAOYSA-N Cc1c(C(NC2CC2)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 Chemical compound Cc1c(C(NC2CC2)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 JBYGMRAUWMALBQ-UHFFFAOYSA-N 0.000 description 1
- GCZHNJOCAPYVPG-UHFFFAOYSA-N Cc1c(C(NCC(c2ccccc2)O)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 Chemical compound Cc1c(C(NCC(c2ccccc2)O)=O)[nH]c(C)c1-c1ccnc(Nc2ccccc2)n1 GCZHNJOCAPYVPG-UHFFFAOYSA-N 0.000 description 1
- YDMCMQDSOZIWQR-UHFFFAOYSA-N Cc1c(C(NCc(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(N)nc1)c1F Chemical compound Cc1c(C(NCc(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(N)nc1)c1F YDMCMQDSOZIWQR-UHFFFAOYSA-N 0.000 description 1
- SPRBYTSAHQAMRV-UHFFFAOYSA-N Cc1c(C(NCc(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(Nc(c(F)c1)ccc1Cl)nc1)c1O Chemical compound Cc1c(C(NCc(cc2)ccc2F)=O)[nH]c(C)c1-c(nc(Nc(c(F)c1)ccc1Cl)nc1)c1O SPRBYTSAHQAMRV-UHFFFAOYSA-N 0.000 description 1
- JRJSETHPKUHHBN-OAHLLOKOSA-N Cc1c(C(N[C@H](CN)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c1ccnc(N)n1 Chemical compound Cc1c(C(N[C@H](CN)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c1ccnc(N)n1 JRJSETHPKUHHBN-OAHLLOKOSA-N 0.000 description 1
- ZSHJTSUXBCKRJD-HXUWFJFHSA-N Cc1c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c1ccnc(N2CCCCC2)n1 Chemical compound Cc1c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)[nH]c(C)c1-c1ccnc(N2CCCCC2)n1 ZSHJTSUXBCKRJD-HXUWFJFHSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N OC1CCCCC1 Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45440503P | 2003-03-13 | 2003-03-13 | |
| US60/454,405 | 2003-03-13 | ||
| PCT/US2004/007540 WO2004083203A1 (en) | 2003-03-13 | 2004-03-11 | Compositions useful as protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006520386A JP2006520386A (ja) | 2006-09-07 |
| JP2006520386A5 true JP2006520386A5 (https=) | 2007-05-10 |
| JP4808154B2 JP4808154B2 (ja) | 2011-11-02 |
Family
ID=33029879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507111A Expired - Fee Related JP4808154B2 (ja) | 2003-03-13 | 2004-03-11 | プロテインキナーゼインヒビターとして有用な組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7456190B2 (https=) |
| EP (1) | EP1606284B1 (https=) |
| JP (1) | JP4808154B2 (https=) |
| AT (1) | ATE450530T1 (https=) |
| AU (1) | AU2004221881A1 (https=) |
| CA (1) | CA2522176A1 (https=) |
| DE (1) | DE602004024374D1 (https=) |
| WO (1) | WO2004083203A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2005105780A2 (en) * | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| UA84930C2 (ru) | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2006071644A1 (en) * | 2004-12-23 | 2006-07-06 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinases and uses therof |
| FR2881742B1 (fr) * | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
| US20080214560A1 (en) * | 2005-10-03 | 2008-09-04 | Astrazeneca Ab | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease |
| UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| WO2007120593A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | Anilino-pyrimidine phenyl and benzothiophene analogs |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| AU2009316264B2 (en) | 2008-11-24 | 2016-09-15 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| US20100136096A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100135984A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100136095A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| US20100137246A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
| US20100137787A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Delivery devices for modulating inflammation |
| US20120077813A1 (en) | 2009-04-15 | 2012-03-29 | Astrazeneca Ab | Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease |
| JP2014500254A (ja) * | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体 |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| EP3407901B1 (en) | 2016-01-29 | 2021-07-21 | Massachusetts Eye & Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
| EP4118081A1 (en) * | 2020-03-27 | 2023-01-18 | Landos Biopharma, Inc. | Plxdc2 ligands |
| WO2025264278A1 (en) * | 2024-06-18 | 2025-12-26 | Memorial Sloan-Kettering Cancer Center | Erk2 degraders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1311336A (en) * | 1970-09-07 | 1973-03-28 | Ici Ltd | Quaternary salts of pyrolylpyridine derivatives |
| AU1274295A (en) * | 1993-12-30 | 1995-07-17 | Ciba-Geigy Ag | Heteroarylpyrroles |
| EP0842923B1 (en) * | 1995-06-07 | 2006-03-01 | Nippon Shinyaku Company, Limited | Pyrrole derivatives and medicinal composition |
| AU7529096A (en) * | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
| JP3455230B2 (ja) * | 1996-07-11 | 2003-10-14 | ファイザー製薬株式会社 | インターロイキン―およびｔｎｆアンタゴニストとして有用なピリジルピロール化合物 |
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| JPH10324687A (ja) * | 1997-02-19 | 1998-12-08 | Nippon Soda Co Ltd | ピロール化合物、製法および農園芸用殺菌剤 |
| CA2374559A1 (en) * | 1999-05-14 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| JP2001247564A (ja) * | 1999-07-21 | 2001-09-11 | Sankyo Co Ltd | ヘテロアリール置換ピロール誘導体 |
| JP2002284780A (ja) * | 2001-01-22 | 2002-10-03 | Sankyo Co Ltd | ４又は５置換ピロール誘導体 |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| KR20050053694A (ko) * | 2002-09-27 | 2005-06-08 | 얀센 파마슈티카 엔.브이. | 3, 4-이치환된 피롤 및 염증 질환을 치료하기 위한 그의용도 |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| UA84930C2 (ru) * | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения |
-
2004
- 2004-03-11 US US10/798,766 patent/US7456190B2/en not_active Expired - Fee Related
- 2004-03-11 WO PCT/US2004/007540 patent/WO2004083203A1/en not_active Ceased
- 2004-03-11 CA CA002522176A patent/CA2522176A1/en not_active Abandoned
- 2004-03-11 AT AT04719833T patent/ATE450530T1/de not_active IP Right Cessation
- 2004-03-11 DE DE602004024374T patent/DE602004024374D1/de not_active Expired - Lifetime
- 2004-03-11 AU AU2004221881A patent/AU2004221881A1/en not_active Abandoned
- 2004-03-11 EP EP04719833A patent/EP1606284B1/en not_active Expired - Lifetime
- 2004-03-11 JP JP2006507111A patent/JP4808154B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006520386A5 (https=) | ||
| US11958855B2 (en) | Aurora kinase inhibitors for inhibiting mitotic progression | |
| EP3023101B1 (en) | Therapeutic agent for fgfr inhibitor-resistant cancer | |
| CN109983016B (zh) | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 | |
| JP2020528907A5 (https=) | ||
| HUE031624T2 (en) | Pyridone derivative | |
| CA2958503A1 (en) | Indazole compounds as fgfr kinase inhibitor, preparation and use thereof | |
| KR20190044499A (ko) | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
| EP4177247A1 (en) | Heterocyclic immunomodulator | |
| KR20230026445A (ko) | 산화아릴인 화합물 및 이의 용도 | |
| CN104774184A (zh) | α-氰基-α,β-不饱和酰胺类化合物及其医药用途 | |
| CN103965211A (zh) | 含喹唑啉结构的三环类衍生物及其制备方法和用途 | |
| CN113264938B (zh) | 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用 | |
| KR20250016122A (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
| CN112442105A (zh) | 作为蛋白激酶抑制剂的新型嘧啶并[4,5-d]嘧啶-2-酮衍生物 | |
| CN113563341B (zh) | 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 | |
| AU2014280932B2 (en) | Compounds for inhibiting mitotic progression | |
| CA3004007A1 (en) | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | |
| KR20260017825A (ko) | 헤테로아릴 유도체 화합물 및 이의 용도 | |
| HK1217699B (en) | Compound for inhibiting mitotic progression | |
| HK1175777B (en) | Compound for inhibiting mitotic progression | |
| HK1134672B (en) | Compounds for inhibiting mitotic progression |